Repositioning Candidate Details
| Candidate ID: | R0633 |
| Source ID: | DB04872 |
| Source Type: | investigational |
| Compound Type: | small molecule |
| Compound Name: | Osanetant |
| Synonyms: | Osanetant |
| Molecular Formula: | C35H41Cl2N3O2 |
| SMILES: | CN(C(C)=O)C1(CCN(CCC[C@@]2(CCCN(C2)C(=O)C2=CC=CC=C2)C2=CC(Cl)=C(Cl)C=C2)CC1)C1=CC=CC=C1 |
| Structure: |
|
| DrugBank Description: | Developed by Sanofi-Aventis (formerly Sanofi-Synthelabo), osanetant (SR-142801) is an NK3 receptor antagonist which was under development for the treatment of schizophrenia and other Central Nervous System (CNS) disorders. In a review of its R&D portfolio, the company announced in August 2005 that it would cease any further development of osanetant. This follows an earlier decision to discontinue development of eplivanserin for schizophrenia. |
| CAS Number: | 160492-56-8 |
| Molecular Weight: | 606.625 |
| DrugBank Indication: | Potential therapy for schizophrenia, depression and visceral pain. |
| DrugBank Pharmacology: | Osanetant is a neurokinin-3 (NK3) receptor antagonist. Preliminary clinical trials have demonstrated that osanetant is superior to placebo on global assessment of efficacy and measures of positive symptoms in schizophrenia. |
| DrugBank MoA: | The mechanism of action of osanetant is uncertain at this point. Various preclinical data indicate that activation of NK3 receptors enhances the release of biogenic amines, including dopamine and serotonin. NK3 receptor antagonists could block NK3-receptor-mediated activation of these systems. |
| Targets: | Neuromedin-K receptor |
| Inclusion Criteria: | Indication associated |
